TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or greater~* Moderate to severe CKD not requiring dialysis (eGFR 15 - 45 ml/min/1.73 m2 by CKD-EPI)~* Absolute iron deficiency (serum ferritin \<300ng/ml and Transferrin Saturation \< 30%)~Exclusion Criteria:~* Hemoglobin concentrations \> 13 g/dL~* Known disorder of iron homeostasis (e.g., hemochromatosis)~* Known gastrointestinal disorder (irritable bowel disease, inflammatory bowel disease)~* Known liver disease (ALT/AST or bilirubin \> 3x normal)~* Serum phosphorus concentrations \< 3.0 mg/dL~* Any known cause of anemia other than iron deficiency or CKD (e.g., sickle cell anemia)~* Symptomatic gastrointestinal bleeding within 12 weeks prior to the screening visit.~* Subjects receiving any form of renal replacement therapy including hemodialysis, peritoneal dialysis, or renal transplant.~* Pregnancy or lactation in female participants~* Severe anemia defined as a hemoglobin \< 8.0 g/dL for males or a hemoglobin \<7.0 g/dL for females.~* Receipt of erythropoiesis stimulating agents within 4 weeks of screening.~* Receipt of intravenous iron therapy within 8 weeks of screening.~* Blood transfusion within 4 weeks of screening~* Known allergies or severe adverse reactions to previous oral iron therapy~* Current use of oral phosphorus binders.~* Current use of an active vitamin D analog

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ferric citrate (Type: EXPERIMENTAL): Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
- ferrous sulfate (Type: ACTIVE_COMPARATOR): Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with active rheumatoid arthritis~* at least 3 months of treatment with methotrexate~Exclusion Criteria:~* have allergies to infliximab~* serious infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P13 (Type: ACTIVE_COMPARATOR): None
- Remicade (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female healthy adult subjects willing to sign a patient information and consent form (PICF) and able to undergo protocol related procedures.~* Age: 18 to 55 years, inclusive.~* Body Mass Index (BMI): 18.5 to 32.0 kg/m2.~* No history or evidence of a clinically significant disorder, condition, or disease that, in the opinion of the investigator would pose a risk to subject safety.~* Resting supine systolic blood pressure of ≤150 mmHg and diastolic blood pressure of ≤90 mmHg. Other vital signs showing no clinically relevant deviations according to the investigator's judgment.~* 12-lead ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the investigator.~* Negative urine drug screen and negative alcohol breath test at screening and admission.~Exclusion Criteria~* Subjects will be excluded from the study if one or more of the following criterion are applicable:~* Evidence of clinically relevant pathology~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to agent(s) used in study.~* Known history of previous exposure to adalimumab or other anti TNF-alpha molecules.~* Subjects with a recent (within 6 months of dosing) infection requiring hospitalisation or intravenous antibiotic use.~* Subjects with a recent (within 4 weeks of dosing) infection requiring oral or systemic antibiotics.~* Subject with a history of recurrent or chronic infections.~* Subject has a positive test for tuberculosis (TB) during screening or a known history of active or latent TB, except documented and complete adequate treatment of TB.~* Having received live vaccines during the 4 weeks before screening or have the intention to receive vaccination during the study.~* Participation in a drug study within 60 days or 5 half-lives of the previous drug (if known), whichever is longer, prior to drug administration Note: Only the few inclusion/exclusion criteria are mentioned here. Subjects will be screened and randomized as per the full list of inclusion and exclusion criteria in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- AVT02 100mg/mL (Type: EXPERIMENTAL): Biosimilar Adalimumab AVT02
- EU-Humira 100mg/mL (Type: ACTIVE_COMPARATOR): EU Approved Adalimumab originator Humira
- US-Humira 100mg/mL (Type: ACTIVE_COMPARATOR): US licensed Adalimumab originator Humira

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PID with hypo- or agammaglobulinemia requiring IgG replacement therapy~* Intravenous IgG (IVIG) therapy at regular 3- or 4-week intervals at a stable dose for at least 3 doses prior to signing of informed consent~* Written informed consent~Exclusion Criteria:~* Newly diagnosed PID, i.e., subjects who have not previously received immunoglobulin replacement therapy~* Ongoing serious bacterial infections (SBIs: pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess) at the time of screening~* Ongoing or history of concomitant malignancies of lymphoid cells such as lymphocytic leukemia, non-Hodgkin's lymphoma, and immunodeficiency with thymoma~* Allergic or other severe reactions to immunoglobulins or other blood products recorded in the past 3 months or at the time of screening~* Pregnancy or nursing mother~* A positive result at screening on any of the following viral markers: human immunodeficiency virus-1 (HIV-1), HIV-2, hepatitis C virus, or hepatitis B virus~* Participation in a study with other investigational product during this study and within 3 months prior to screening~* Subjects who donated blood (200 mL within one month or 400 mL within 3 months prior to screening), or planning to donate blood during the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of S-1 Plus LV for Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically conﬁrmed metastatic or recurrent gastric cancer~* with at least one measurable lesion by RECIST criteria~* an age of ≥ 18~* adequate oral intake~* no previous radiotherapy, immunotherapy, biotherapy, hormonotherapy and chemotherapy within 5 years (adjuvant chemotherapy without S-1 was allowed if ﬁnished 6 months before enrollment)~* an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* adequate bone marrow function, hepatic function and renal functions~Exclusion Criteria:~* a history of hypersensitivity to S-1 or LV, usage of drugs interacting with S-1~* serious concomitant conditions (severe heart disease, pulmonary ﬁbrosis, intestinal obstruction, enteroplegia, renal failure, liver failure, pre-existing sensory neuropathy ≥ grade 2, uncontrolled infections, psychogenic disorders, human immunodeﬁciency virus infection, severe diarrhea, nausea, or vomiting, severe ascites or pleural effusion, etc.)~* extensive bone metastasis, brain metastasis or meningeal metastasis~* another synchronous cancer~* surgery within 3 weeks before enrollment~* participating in other clinical studies~* women who were or to be pregnant, nursing infants, and men who were to conceive children

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1 plus LV (Type: EXPERIMENTAL): All patients were orally treated with S-1 in doses of 40 mg (body surface area (BSA)\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non Operative Treatment for Acute Appendicitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>14 years~2. Lower / RIF Abdominal Pain~3. Clinical Suspicion of Acute Appendicitis:~   i.e.~  * Alvarado Score 5-6 (equivocal for acute appendicitis)~  * Alvarado Score 7-8 (probably appendicitis)~  * Alvarado Score 9-10 (highly likely appendicitis)~4. Informed consent (patient or legal representative)~Exclusion Criteria:~1. Diffuse peritonitis~2. Antibiotic (Penicillin) documented allergy~3. Ongoing previously started antibiotic therapy~4. Previous appendectomy~5. Positive pregnancy test~6. IBD history or suspicion of IBD recrudescence

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non operative Treatment group (Type: EXPERIMENTAL): Patients with Lower Abdominal and suspected Acute Appendicitis, treated non-operatively with 7 days antibiotic therapy (Amoxicillin and Clavulanic Acid)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Clarithromycin in Septic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. written informed consent provided by first or second degree relatives;~2. intubation and mechanical ventilation at least 48 hours prior to enrolment; c) age of patients equal to or more than 18 years;~d) diagnosis of Ventilator Associated Pneumonia; and e) signs of sepsis~Exclusion Criteria:~1. neutropenia, defined as less than 500 neutrophils/mm3;~2. HIV infection;~3. oral intake of corticosteroids at a dose equal to or higher than 1mg/kg equivalent prednisone for a period greater than one month;~4. administration of drotrecogin alpha the last five days prior to enrolment; and e) atrioventricular block of second or third degree.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized male and female subjects with clinically documented nosocomial pneumonia proven to be due to methicillin-resistant staphylococcus aureus.~* Chest X-ray at baseline/screen or within 48 hours of treatment consistent with the diagnosis of pneumonia.~* Suitable sputum specimen defined as having less than 10 squamous epithelial cells and greater or equal 25 leukocytes or have a culture taken by an invasive technique within 24 hours of study entry.~Exclusion Criteria:~* Subjects who were treated with a previous antibiotic with MRSA activity (other than linezolid or vancomycin) for more than 48 hours, unless documented to be a treatment failure (72 hours of treatment and not responding).~* Subjects with severe neutropenia (\<500 cells/mm3)~* Subjects with hypersensitivity to oxazolidinones or vancomycin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Subjects receiving linezolid for the treatment phase of the study
- 2 (Type: ACTIVE_COMPARATOR): Subjects receiving vancomycin for the treatment phase of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Bifidus DR10 and Oligo Saccharides / Micronutrient Fortification of Milk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children aged 12-36 months at enrollment~* Resident of Sangam Vihar and likely to be in the area for 1 year.~* Parents consenting to participate in the trial.~Exclusion Criteria:~* Children who have been given complete therapeutic/preventive course of Iron in the last 6 months.~* Children currently as part of a different Iron/Zinc supplementation program.~* Children known to be allergic to milk.~* Children who are severely malnourished and requiring hospitalization.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion~* Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures~* Patient achieved complete clearance of AK lesions (lesion count of 0) in the selected treatment area at the Day 57 visit in study PEP005-020~Exclusion~* Concurrent participation in another research study which would involve the selected treatment area (except for any post-study follow-up visits for previous Peplin AK study)~* Early termination from study PEP005-020

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Childhood Apraxia of Speech

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Native English speakers who hear English as the dominant language in their home setting.~* Must pass a hearing screening.~* Score at or better than -2 standard deviations from the mean on the Matrix Reasoning Task of the Wechsler Abbreviated Scale of Intelligence - 2nd Edition (WASI-2; t-score ≥ 30), Peabody Picture Vocabulary Test - 4th Edition (PPVT-4; standard score ≥ 70), and the Following Directions subtest of the Clinical Evaluation of Language Fundamentals - 5th Edition (CELF-5; scaled score ≥ 3).~* Goldman-Fristoe Test of Articulation - 3rd Edition (GFTA-3) percentile ≤ 5th).~* A diagnosis of CAS will be verified based on a polysyllable picture naming task, diadochokinetic task (puh-tuh-kuh), and syllable repetition task.~Exclusion Criteria:~* Parent report or direct evaluation reveals oral-facial structural abnormalities (e.g., cleft palate).~* Parental report of neurobehavioral disorders (e.g., autism spectrum disorders, ADHD, obsessive-compulsive disorder), or vision problems that are corrected with glasses/contacts.~* Fail a hearing screening, or failure to meet criteria listed above as Inclusionary

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Biofeedback, Massed->Distributed (Type: EXPERIMENTAL): Sequenced biofeedback Mass Practice--\> Distributed Scheduling
- No Biofeedback, Distributed (Type: ACTIVE_COMPARATOR): Speech Motor Chaining with no biofeedback. 2 sessions/wk for 10 weeks
- Biofeedback, Distributed (Type: EXPERIMENTAL): Sequenced biofeedback, 2 sessions/wk for 10 weeks
- No Biofeedback, Massed-> Distributed (Type: EXPERIMENTAL): Speech Motor Chaining with no biofeedback. Mass Practice--\> Distributed Scheduling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* At least 18 years of age at the time of consent~* Measurable disease~* All necessary baseline studies completed~* LVEF (left ventricular ejection fraction) greater than or equal to 50 percent by MUGA (multigated acquisition scan) or ECHO (echocardiogram)~* Must be able to adhere to study visit schedule~Exclusion~* Greater than or equal to grade 2 peripheral neuropathy on clinical examination within 14 days of enrollment~* Renal insufficiency~* Evidence of mucosal or internal bleeding and/ or platelet refractory.~* Absolute neutrophil count less than 1000 cells/mm\^2 within 14 days of enrollment.~* Acceptable labs~* Concomitant medications that include corticosteroids~* Myocardial infarction within 6 months prior to enrollment, uncontrolled angina, severe uncontrolled ventricular arrhythmias~* Clinically relevant active infection or serious medical condition that places the subject at unacceptable risk~* Any condition, including laboratory values that places the subject at an unacceptable risk~* Another malignancy within 3 years of enrollment, with the exception of the complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low risk prostate cancer after curative therapy~* Hypersensitivity to bortezomib, boron, or mannitol or any of the components of DOXIL~* Female subject that is pregnant or breastfeeding.~* Can not have received any other investigational drugs within 14 days of enrollment~* Serious medical or psychiatric illness~* Uncontrolled diabetes mellitus~* Hypersensitivity to acyclovir or similar antiviral drug~* POEMS (plasma cell dyscrasia with polyneuropathy)~* Known HIV~* Known hepatitis B or C~* Known intolerance to steroid therapy~* Known hypersensitivity to required prophylactic mediations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Drug Therapy (Type: EXPERIMENTAL): Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11, Doxil at indicated doses on day 4, Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels, and Revlimid at indicated doses on days 1-14 in 3-week cycles for 4-8 cycles. To determine the MTD of the combination of Revlimid, Velcade, dexamethasone, and Doxil, four dose levels are planned.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a diagnosis of Epilepsy with Simple Partial Seizures (motor component) and or Complex Partial Seizures (with or without secondary generalization)~* Must be experiencing 2 to 40 seizures per 28-day period~* Stable dose of 1 or 2 marketed antiepileptic drugs~* Second Antiepileptic Drug (AED) must be less than or equal to 50 % of the minimum recommended maintenance dose per USA product label at screening~Exclusion Criteria:~* Subject has a history of primary generalized or unclassified seizures~* Seizure disorder primarily characterized by isolated auras~* History of status epilepticus~* Seizures that are uncountable due to clustering~* Has greater than 5 seizures/day~* Subjects taking Benzodiazepines, Phenobarbital or Primidone~* Subject has Vagus Nerve Stimulation (VNS)~* Significant medical or psychiatric condition~* History of alcohol or drug abuse~* History of Ethosuximide use, Felbamate use after 1994 or Vigabatrin use after 1997

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide 400 mg/day (Type: EXPERIMENTAL): Lacosamide 400 mg/day
- Lacosamide 300 mg/day (Type: ACTIVE_COMPARATOR): Lacosamide 300 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete